Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre Observational Study on Treatment Approaches and HER2 Positive Status Prevalence in Different Stages of Bladder Cancer and PD-L1-positive Status in Metastatic Bladder Cancer in Russian Federation

NCT07038928 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07038928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07038928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre Observational Study on Treatment Approaches and HER2 Positive Status Prevalence in Different Stages of Bladder Cancer and PD-L1-positive Status in Metastatic Bladder Cancer in Russian Federation
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
June 30, 2025
Completion date
December 31, 2026
Enrollment
600 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer